Latest Conference Articles
Stay up to date on the latest oncology and nursing conferences.
Rise of Oral Cancer Drugs Signal Deeper Financial Toxicity Issues for Patients
September 28th 2022, 6:00pm
Mary Anderson, BSN, RN, OCN; and Christina Bach, MBE, MSW, LCSW, OSW-C, FAOSW, discuss approaches to help patients navigate financial toxicity and insurance coverage in the age of oral anticancer drugs.
Promising Pathologic Complete Response Rate Observed With Neoadjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma
September 28th 2022, 2:00pm
Neoadjuvant cemiplimab elicited promising pathologic complete responses in patients with cutaneous squamous cell carcinoma.
Climate Change and Evolving Threats to Public Health: The Oncology Nurse’s Role
September 27th 2022, 2:00pm
Milagros Elia, MA, APRN, ANP-BC, discusses ways that nurses can advocate for their patients and help them manage health-related symptoms in the context of changing local environments.
Addition of Abemaciclib to Aromatase Inhibitor Therapy Prolongs Survival in HR+/HER2- Breast Cancer
September 25th 2022, 2:00pm
For patients receiving an aromatase inhibitor for hormone receptor–positive, HER2-negative breast cancer, the addition of abemaciclib doubled median progression-free survival vs placebo.
Phase 3 Findings Showcase PFS Benefit with Sotorasib for Patients With KRAS G12C+ NSCLC
September 24th 2022, 2:00pm
Sotorasib doubled the progression-free survival rate in patients with KRAS G12C–mutated non–small cell lung cancer.
Nurse-Led Research Links Saturate Fatty Acids to Improved Immunotherapy Responses in NSCLC
September 23rd 2022, 2:00pm
Julie Malo, CCRP, a research nurse with the University of Montreal, discusses a nurse-directed initiative examining how the gut microbiome affects immune checkpoint blockade responses in patients with non–small cell lung cancer.
Tislelizumab Rivals Sorafenib in Improving OS in Unresectable Hepatocellular Carcinoma
September 22nd 2022, 6:00pm
Patients with hepatocellular carcinoma achieved a median overall survival of 15.9 months with tislelizumab and 14.1 months with sorafenib.
Lenvatinib Dose Escalation Is Associated With Favorable Outcomes in Patients with HCC
September 21st 2022, 6:00pm
In a real-world analysis of patients with hepatocellular carcinoma, the median overall survival with lenvatinib was 9.7 months in the low-dose group and 7.6 months in the recommended-dose group.
Oncology Nurses Must Understand the Later Effects of HSCT To Provide Adequate Survivorship Care
September 21st 2022, 2:00pm
In a presentation at the 2022 Oncology Nursing Society Bridge, Stephany L. Rodriguez, RN, MS, NP, discussed the later effects associated with hematopoietic stem cell transplant and how to manage them.
Daly Discusses Biomarkers and Emerging Targeted Therapies for Cancer Care
September 20th 2022, 6:00pm
Kristin Daly, MSN, ANP-BC, AOCNP, discusses the clinical significance of tumor variants and how they are changing the direction of cancer care.